	US 11,813,274 B2
	Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor
Li Chen, Shanghai (CN); Shuang Ren, Shanghai (CN); and Jiayi Zhang, Shanghai (CN)
Assigned to HUA Medicine (Shanghai) Ltd., Shanghai (CN)
Filed by HUA Medicine (Shanghai) Ltd., Shanghai (CN)
Filed on Apr. 21, 2021, as Appl. No. 17/236,393.
Claims priority of provisional application 63/013,914, filed on Apr. 22, 2020.
Prior Publication US 2021/0330690 A1, Oct. 28, 2021
Int. Cl. A61K 31/7048 (2006.01); A61K 31/4155 (2006.01); A61P 3/10 (2006.01); A61K 9/20 (2006.01); A61K 9/00 (2006.01)

CPC A61K 31/7048 (2013.01) [A61K 9/0053 (2013.01); A61K 9/20 (2013.01); A61K 31/4155 (2013.01); A61P 3/10 (2018.01)]

29 Claims

1. A method of treating a treatment-resistant diabetes, comprising administering to a subject in need thereof a therapeutically effective amount of a glucokinase activator and a therapeutically effective amount of a sodium-glucose cotransporter-2 inhibitor;

wherein the glucokinase activator is (S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(1-((R)-2,3-dihydroxypropyl)-1H-pyrazol-3-yl)-4-methylpentanamide, or a tautomer, or a mixture of two or more tautomers thereof; or a pharmaceutically acceptable salt thereof; and

wherein the sodium-glucose cotransporter-2 inhibitor is bexagliflozin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, phlorizin, remogliflozin, serglifozin, sotagliflozin, or tofogliflozin; or a tautomer, or a mixture of two or more tautomers thereof; or a pharmaceutically acceptable salt thereof.